CFRXQ (ContraFect) Float Percentage Of Total Shares Outstanding: 89.42% (As of Jul. 08, 2026)


What is ContraFect Float Percentage Of Total Shares Outstanding?

ContraFect CFRXQ -90.00% Float Percentage Of Total Shares Outstanding is 89.42% as of Jul. 08, 2026.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ContraFect's float shares is 9.57 Mil. ContraFect's total shares outstanding is 10.70 Mil. ContraFect's float percentage of total shares outstanding is 89.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ContraFect's Insider Ownership is 13.62%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ContraFect's Institutional Ownership is 0.00%.

ContraFect Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ContraFect's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=9.57/10.70
=89.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 89.42% mean?
ContraFect (CFRXQ) has a Float Percentage Of Total Shares Outstanding of 89.42% as of Jul. 08, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on ContraFect and its competitors.
Is ContraFect's Float Percentage Of Total Shares Outstanding too high?
ContraFect's current Float Percentage Of Total Shares Outstanding is 89.42%.
How does ContraFect's Float Percentage Of Total Shares Outstanding compare to ADTX and RUBY?
ContraFect's Float Percentage Of Total Shares Outstanding of 89.42% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on ContraFect and its competitors. ContraFect's current Float Percentage Of Total Shares Outstanding is 89.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ContraFect stock overvalued right now?
ContraFect (CFRXQ) has a current Float Percentage Of Total Shares Outstanding of 89.42%. The current Float Percentage Of Total Shares Outstanding is 89.42%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For ContraFect (CFRXQ), the current Float Percentage Of Total Shares Outstanding is 89.42% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ContraFect Business Description

Address 28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.